20 completed, 8 terminated, 4 unknown, 2 active not recruiting. 36 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Completed 20, Terminated 8, Unknown 4, Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Recruiting 1 |
Follow Haloperidol: new trials by email Literature Review of Haloperidol trials Research Report on Haloperidol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department Olanzapine 10 milligram, Haloperidol - Cannabinoid Hyperemesis Syndrome | Phase 3 | Completed | Mercy Bon Secours Saint Vincent Medical Center | 31 | 2025-11-06 | 2026-10-14 |
| Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult Dexmedetomidine, Lorazepam, Haloperidol - Altered Mental Status | Phase 3 | Unknown | State University of New York - Upstate Medical University | 60 | 2024-06-01 | 2024-04-22 |
| Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium Quatiapine, Haloperidol - Hyperactive Delirium | Phase 3 | Completed | Alexandria University | 100 | 2023-04-09 | 2023-08-30 |
| A Study of Olanzapine in Patients With Acute Agitation Olanzapine, Haloperidol - Acute Agitation | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 318 | 2023-03-28 | 2023-04-07 |
| Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly Haloperidol Injection - Delirium in Old Age | Phase 2 / Phase 3 | Completed | Ain Shams University | 135 | 2022-11-01 | 2023-12-13 |
| Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy Haloperidol, Chlorpromazine, Valproate - Delirium, Epileptics | Phase 2 / Phase 3 | Recruiting | M.D. Anderson Cancer Center | 42 | 2022-07-19 | 2025-11-18 |
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial Haldol 2mg/ml oral solution, Olanzapine Actavis 5mg orodispersible tablet - Haloperidol, Advanced Cancer | Phase 3 | Completed | Tan Tock Seng Hospital | 22 | 2022-05-18 | 2026-10-05 |
| Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis Droperidol, Haloperidol, Ondansetron 8mg - Cyclic Vomiting Syndrome | Phase 3 | Terminated | Corewell Health South | 32 | 2021-08-30 | 2025-05-21 |
| Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY) Customized Adherence Enhancement, Haloperidol Decanoate - Schizophrenia, Medication Nonadherence | Phase 3 | Completed | Case Western Reserve University | 22 | 2019-11-05 | 2021-10-12 |
| Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care Haloperidol, Lorazepam, Placebo - Delirium, Locally Advanced Malignant Neoplasm | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 110 | 2019-07-17 | 2026-06-15 |
| Haloperidol for Delirium in Adult Critically Ill Patients Haloperidol, Placebo - Delirium, Critical Illness | Phase 3 | Terminated | Erasmus Medical Center | 142 | 2018-02-22 | 2022-05-11 |
| Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer Chlorpromazine, Haloperidol, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Delirium | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 70 | 2017-06-05 | 2026-09-14 |
| Treatment of Hypoactive Delirium and Outcome Measures Haloperidol, Placebo, non-pharmacologic measures - Hypoactive Delirium | Phase 3 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 60 | 2016-01-01 | 2017-04-21 |
| A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform Aripiprazole, Haloperidol, Olanzapine - Schizophrenia, Psychotic Disorders | Phase 3 | Completed | Janssen Scientific Affairs, LLC | 337 | 2015-07-08 | 2025-04-29 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium Haloperidol, Placebo - Postoperative Confusion | Phase 3 | Completed | McMaster University | 25 | 2013-08-01 | 2016-09-16 |
| Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium Quetiapine, Haloperidol, Placebo - Delirium | Phase 3 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 107 | 2013-02-01 | 2018-02-09 |
| Haloperidol vs. Valproate in Agitation Haloperidol, Valproate - Psychomotor Agitation | Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | 56 | 2012-12-01 | 2013-01-08 |
| Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Discontinuation antipsychotic treatment, Antipsychotic treatment - Psychosis Nos/Other | Phase 3 | Unknown | Fundación Pública Andaluza Progreso y Salud | 104 | 2012-11-01 | 2014-12-05 |
| The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study Haloperidol, Ziprasidone, Placebo - Delirium, Impaired Cognition | Phase 3 | Completed | Vanderbilt University Medical Center | 566 | 2011-12-14 | 2019-11-18 |
Showing 20 of 36. Sign in to see all of them.
Delirium (10) · Schizophrenia (9) · Psychomotor Agitation (4) · Psychotic Disorders (3) · Bipolar Disorder (2) · Neoplasm Metastasis (2) · Recurrence (2) · Aggression (1) · Alzheimer Disease (1) · Anxiety Disorders (1) · Behavioral Symptoms (1) · Cannabinoid Hyperemesis Syndrome (1) · Cognition Disorders (1) · Cognitive Dysfunction (1) · Confusion (1)
M.D. Anderson Cancer Center (3) · Eli Lilly and Company (2) · Organon and Co (2) · Ain Shams University (1) · Alberta Health services (1) · Alexandria University (1) · Beersheva Mental Health Center (1) · Bronovo Hospital (1) · Case Western Reserve University (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Chiang Mai University (1) · Corewell Health South (1) · Duke University (1) · Erasmus Medical Center (1) · Fundación Pública Andaluza Progreso y Salud (1)
United States (10) · Canada (3) · Egypt (3) · Mexico (3) · Netherlands (3) · Brazil (2) · Taiwan (2) · Bulgaria (1) · China (1) · Croatia (1) · Germany (1) · India (1) · Iran (1) · Israel (1) · Japan (1)
David Hui (2) · Adel Elsheshai, MD (1) · Andre Lamy, MD (1) · Baruch Spivak, MD (1) · Benchalak Maneeton, Assoc Prof (1) · Chanoch Midownik, MD (1) · David Hui, MD (1) · E. Wesley Ely, MD, MPH (1) · Eric B Milbrandt, MD, MPH (1) · Erwin Chiquete, MD, PhD (1)
PMID 11087767, PMID 18041437, PMID 20520283, PMID 22134043, PMID 22144928, PMID 22950484, PMID 23422376, PMID 23926422, PMID 25367164, PMID 25791540, PMID 28781452, PMID 30346242, PMID 32029262, PMID 32479786, PMID 32967873, PMID 33692709, PMID 33728561, PMID 34238838, PMID 34546899, PMID 34820831, PMID 35086504, PMID 35247794, PMID 35939921, PMID 35971024, PMID 36448276, PMID 37004331, PMID 37756123, PMID 37904241, PMID 38252439, PMID 38701817, PMID 38958149, PMID 40198074, PMID 40742738, PMID 41739187, PMID 41778148
K23HL078760 (1), R21MH114700 (1), R21NR016736 (1), U01AG010483 (1)